QOL Not Affected by Active Surveillance of Prostate Cancer

This article originally appeared here.
Share this content:
QOL Not Affected by Active Surveillance of Prostate Cancer
QOL Not Affected by Active Surveillance of Prostate Cancer

FRIDAY, July 29, 2016 (HealthDay News) -- Men with low-risk prostate cancer report a good quality of life after choosing active surveillance as a treatment for their disease, according to research published in the August issue of The Journal of Urology.

The new study included 89 American men with low-risk prostate cancer and 420 men without the disease.

Over three years of follow-up, there were no significant differences between the two groups in health-related quality of life.

"Our results suggest that for at least three years, men selecting active surveillance do not experience a substantial psychological burden or clinically significant problems due to untreated disease," lead investigator Christopher Porter, M.D., from the Virginia Mason Medical Center in Seattle, said in a journal news release. "The potential clinical impact of these results is significant and will allow clinicians to counsel patients effectively in regard to the potential health-related quality-of-life outcomes associated with active surveillance."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »